Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Hydromorphone + oxycodone is a combination of two potent opioid analgesics used for the management of severe pain when alternative treatments are inadequate. Both drugs act primarily as agonists at the mu-opioid receptor in the central nervous system, altering pain perception and response. Hydromorphone is a hydrogenated ketone analogue of morphine, while oxycodone is a semisynthetic opioid derived from thebaine. Both medications are associated with risks of dependence, tolerance, and typical opioid side effects such as respiratory depression, sedation, constipation, and euphoria[1][2][3][6][8]. They are available in various formulations for oral administration and are typically reserved for cases where non-opioid analgesics fail to provide adequate relief.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on hydromorphone + oxycodone.